ScaleReady announces a G-Rex® Grant has been awarded to renowned cancer immunologist Dr. Christopher A. Klebanoff

Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced the awarding of a $300,000 G-Rex Grant to Dr. Christopher A. Klebanoff for the development of a novel CD8α/β armored TCR-T cell therapy targeting a specific neoantigen in a Phase 1 clinical trial [1][2][3] Company and Industry Overview - The G-Rex Grant aims to facilitate process development, IND-enabling studies, and support clinical manufacturing for the TCR-T cell therapy, which is designed to target specific cancer cell antigens [1][3][4] - The G-Rex Grant Program is a $20 million initiative to advance cell and gene-modified cell therapy (CGT) development and manufacturing, providing individual grants up to $300,000 [8] - ScaleReady's G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials, as well as five commercially approved CGT drugs [9] - Bio-Techne is collaborating with Wilson Wolf to create tailored products for G-Rex Bioreactors, enhancing the efficiency of reagent preparation in GMP manufacturing settings [11]